Anti-BCMA chimeric antigen receptor T cell therapy (Shanghai Unicar-Therapy Bio-medicine Technology)

N/A

Report date: 2025/05/21 11:12:26

Base Information

Drug NameAnti-BCMA chimeric antigen receptor T cell therapy (Shanghai Unicar-Therapy Bio-medicine Technology)
Drug Alias NameBCMA-CART
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple MyelomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaIND
Originator CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A